Enfluran' je ekstremno stabilan inhalacioni anestetik koji omogućava brzo prilagođavanja stepena anestezije sa malom promenom pulsa ili respiratorne brzine.[6] [7]
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.” . Drug Discov Today 15 (23-24): 1052-7. DOI :10.1016/j.drudis.2010.10.003 . PMID 20970519 . edit ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4 : 217-241. DOI :10.1016/S1574-1400(08)00012-1 . ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining” . J Cheminform 2 (1): 3. DOI :10.1186/1758-2946-2-3 . PMID 20331846 . edit ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG” . Yeast 17 (1): 48–55. DOI :10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H . ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI :10.1093/nar/gkr777 . PMID 21948594 . edit ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682 . ↑ Nucleic Acids Res (2008). DrugBank: a knowledgebase for drugs, drug actions and drug targets . 36 . pp. D901-6. PMID 18048412 .
Jonotropni
Agonisti: Konkurentni agonisti :
Aspartat •
Glutamat •
Homokinolinska kiselina •
Ibotenska kiselina •
NMDA •
Kinolinska kiselina •
Tetrazolilglicin ;
Agonisti glicinskog mesta: ACBD •
ACPC •
ACPD •
Alanin •
CCG •
Cikloserin •
DHPG •
Fluoroalanin •
Glicin •
HA-966 •
L-687,414 •
Milacemid •
Sarkozin •
Serin •
Tetrazolilglicin ;
Agonisti poliaminskog mesta: Akamprosat •
Spermidin •
Spermin Antagonisti :Konkurentni antagonisti: AP5 (APV) •
AP7 •
CGP-37849 •
CGP-39551 •
CGP-39653 •
CGP-40116 •
CGS-19755 •
CPP •
LY-233,053 •
LY-235,959 •
LY-274,614 •
MDL-100,453 •
Midafotel (d-CPPen) •
NPC-12,626 •
NPC-17,742 •
PBPD •
PEAQX •
Perzinfotel •
PPDA •
SDZ-220581 •
Selfotel ;
Nekonkurentni antagonisti: ARR-15,896 •
Karoverin •
Deksanabinol •
FPL-12495 •
FR-115,427 •
Hodgkinsin •
Magnezijum •
MDL-27,266 •
NPS-1506 •
Psihotridin •
Cink ;
Nekonkurentni blokatori pora: 2-MDP •
3-MeO-PCP •
8A-PDHQ •
Amantadin •
Aptiganel •
ARL-12,495 •
ARL-15,896-AR •
ARL-16,247 •
Budipin •
Delucemin •
Deksoksadrol •
Dekstralorfan •
Dieticiklidin •
Dizocilpin •
Endopsihozin •
Esketamin •
Etoksadrol •
Eticiklidin •
Gaciklidin •
Ibogain •
Indantadol •
Ketamin •
Ketobemidon •
Loperamid •
Memantin •
Meperidin (Petidin) •
Metadon •
Metorfan (
Dekstrometorfan ,
Levometorfan ) •
Metoksetamin •
Milnacipran •
Morfanol (
Dekstrorfan ,
Levorfanol ) •
NEFA •
Nerameksan •
Azotsuboksid •
Noribogain •
Orfenadrin •
PCPr •
Fenciklamin •
Fenciklidin •
Propoksifen •
Remacemid •
Rinhofilin •
Riluzol •
Rimantadin •
Roliciklidin •
Sabeluzol •
Tenociklidin •
Tiletamin •
Tramadol •
Ksenon ;
Antagonisti glicinskog mesta: ACEA-1021 •
ACEA-1328 •
ACPC •
Karisoprodol •
CGP-39653 •
CKA •
DCKA •
Felbamat •
Gavestinel •
GV-196,771 •
Kinurenska kiselina •
L-689,560 •
L-701,324 •
Lakosamid •
Likostinel •
LU-73,068 •
MDL-105,519 •
Meprobamat •
MRZ 2/576 •
PNQX •
ZD-9379 ;
Antagonisti NR2B podjedinice: Bezonprodil •
CO-101,244 (PD-174,494) •
CP-101,606 •
Eliprodil •
Haloperidol •
Ifenprodil •
Izoksuprin •
Nilidrin •
Ro8-4304 •
Ro25-6981 •
Traksoprodil ;
Neklasifikovani/nesortirani antagonisti: Hloroform •
Dietil etar •
Enfluran •
Etanol (Alkohol) •
Halotan •
Izofluran •
Metoksifluran •
Toluen •
Trihloroetan •
Trihloroetanol •
Trihloroetilen •
Ksilen
Metabotropni
Inhibitori transporta
Molimo Vas, obratite pažnju na važno upozorenje zdravlju (medicini) .
